| abstract |
Simultaneous or sequential administration to treat or ameliorate one or more symptoms of HCV or a disorder associated with HCV in a subject in need of treatment or amelioration of one or more symptoms of HCV or a disorder associated with HCV Disclosed are agents, pharmaceutical compositions, pharmaceutical kits, and methods based on the combination of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor that is not HCV-796. In one embodiment, the at least one HCV protease inhibitor is a compound of structural formula I or a pharmaceutically acceptable salt, solvate or ester thereof. |